Heel 025 Tab 4 D Tablet is a Health Canada–registered human drug (DIN 01969307) held by Biologische Heilmittel Heel GmbH, containing Lobelia Inflata. Health Canada lists its status as Cancelled Post Market (status date 10 Oct 1997). Nexara Health has matched 18 registrations of Lobelia Inflata across 1 other regulated market.
Health Canada registration
| DIN | 01969307 |
|---|---|
| Brand name | Heel 025 Tab |
| Active ingredient | Lobelia Inflata |
| Strength | 4 D |
| Dosage form | Tablet |
| Route | Oral |
| Company | Biologische Heilmittel Heel GmbH |
| Status | Cancelled Post Market — 10 Oct 1997 |
| Class | Human |
| ATC | |
| AHFS | 92:02.00* ; See footnote |
| Regulator record | Health Canada DPD entry · Product monograph |
Lobelia Inflata registered in other markets
18 registrations of the same molecule in 1 national registry outside Canada (first 8 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| United States | Lobelia inflata | Boiron | Pellet | listed | FDA NDC | |
| United States | Lobelia inflata | Boiron | Pellet | listed | FDA NDC | |
| United States | Lobelia inflata | Boiron | Pellet | listed | FDA NDC | |
| United States | Lobelia inflata | Boiron | Pellet | listed | FDA NDC | |
| United States | Lobelia inflata | Boiron | Pellet | listed | FDA NDC | |
| United States | Lobelia inflata | Boiron | Pellet | listed | FDA NDC | |
| United States | Lobelia inflata | Boiron | Pellet | listed | FDA NDC | |
| United States | Lobelia inflata | Boiron | Pellet | listed | FDA NDC |
See every manufacturer of Lobelia Inflata worldwide →
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. This DIN is not currently marketed in Canada. The registrations above show which regulated markets hold an equivalent presentation that can be sourced for clinical comparator use or on a named-patient basis under Health Canada's Special Access Programme. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Heel 025 Tab (DIN 01969307) marketed in Canada?
No. Health Canada lists DIN 01969307 as Cancelled Post Market as of 10 Oct 1997.
Who holds the Canadian licence for this product?
Biologische Heilmittel Heel GmbH is the company of record in the Health Canada Drug Product Database.
Is Lobelia Inflata registered outside Canada?
Yes — Nexara Health has matched 18 registrations in 1 other market (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 01969307, status date 1997-10-10; national medicine registries: FDA NDC. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 01969307, status date 1997-10-10; national medicine registries: FDA NDC.
Health Canada Drug Product Database (DPD), DIN 01969307, status date 1997-10-10; national medicine registries: FDA NDC. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.